It is well documented that the ER signalling plays an important role in the tumorigenesis of ER+ breast cancer, which is the scientific basis of the anti-estrogen therapy (tamoxifen and aromatase inhibitors). The gene discussed is CYP19A1; the disease is breast carcinoma.